Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
“Anticoagulation proteins" refers to a heterogeneous group of endogenous plasma proteins that act to inhibit or regulate blood coagulation, thereby preventing pathological clot formation. Major representatives include antithrombin, protein C, protein S, and tissue factor pathway inhibitor, each controlling different steps in the coagulation cascade. They are clinically relevant as deficiencies or dysfunctions in these proteins dramatically increase the risk of thrombosis, and several therapeutic strategies exploit or enhance the function of these proteins. However, as a term, “anticoagulation proteins” is overly broad and not specific to a single therapeutic target or pathway.
Inhibition of clotting factor activity (e.g., inhibition of thrombin or factor Xa), Potentiation of natural inhibitors (e.g., heparin potentiates antithrombin), Interference with vitamin K-dependent synthesis of factors
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Anticoagulation proteins.